Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeuroSolve: Combined Praziquantel and Albendazole for Neurocysticercosis
NCT06376396Phase 4Not yet recruiting
- Sponsor
- R-Evolution Worldwide
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of praziquantel in neurocysticercosis (NCC), sponsored by R-Evolution Worldwide. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
praziquantel
03
Conditions
neurocysticercosis (NCC)
Beyond the preview
Go deeper on NCT06376396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06376396.